Mark Feitelson
Mark Feitelson received his Ph.D. in Microbiology and Immunology from UCLA in 1979. He began his work on the pathogenesis of chronic hepatitis B at Stanford University and was then recruited to the Fox Chase Cancer Center by Nobel laureate Dr. Baruch Blumberg. In 1991, Dr. Feitelson moved to Thomas Jefferson University where he became a Professor of Pathology and Cell Biology and director of the Molecular Diagnostics Lab in Microbiology. In 2007, Dr. Feitelson was appointed Professor of Biology at Temple University. He is also the CSO of SFA Therapeutics. His work has been supported by NIH, industry and foundations, and he has mentored over 130 students. He has more than 150 publications, 180 abstracts and 11 patents.